Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.72 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.72 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 14/20 | 0.64 |
| ▸ | LCK | P06239 | 7/20 | 0.64 |
| ▸ | CSK | P41240 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 11/20 | 0.62 |
| ▸ | TEK | Q02763 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 11/20 | 0.59 |
| ▸ | ABL1 | P00519 | 9/20 | 0.59 |
| ▸ | HCK | P08631 | 9/20 | 0.59 |
| ▸ | LYN | P07948 | 2/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | YES1 | P07947 | 1/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.59 |
| ▸ | FGR | P09769 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13020182 | 0.93 | BTK (0.64) | BTKNUDT14NUDT5SRCLCK | |
| SCHEMBL13020469 | 0.93 | BTK (0.64) | BTKNUDT14NUDT5SRCLCK | |
| SCHEMBL3781592 | 0.93 | BTK (0.64) | BTKNUDT14NUDT5SRCLCK | |
| SCHEMBL20351824 | 0.91 | BTK (0.75) | BTKNUDT14NUDT5SRCLCK | |
| SCHEMBL3791532 | 0.88 | SRC (0.61) | BTKNUDT14NUDT5SRCLCK | |
| SCHEMBL13019691 | 0.88 | PIK3CD (0.72) | BTKSRCLCKKDREGFR | |
| SCHEMBL13019694 | 0.88 | PIK3CD (0.72) | BTKSRCLCKKDREGFR | |
| SCHEMBL13020127 | 0.88 | EGFR (0.59) | BTKNUDT14NUDT5SRCLCK | |
| SCHEMBL13020162 | 0.87 | SRC (0.62) | BTKNUDT14NUDT5SRCLCK | |
| SCHEMBL13019673 | 0.87 | PIK3CD (0.71) | BTKSRCLCKKDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2009062118-A2 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | BTK 3999/4885NUDT14 1731/4885NUDT5 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.